| Ryan C Rahhal, MD | |
|
6767 South Yale Avenue, Suite A, Tulsa, OK 74136-3303 | |
| (918) 492-7587 | |
| (918) 491-3542 |
| Full Name | Ryan C Rahhal |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 20 Years |
| Location | 6767 South Yale Avenue, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932241742 | NPI | - | NPPES |
| 200220690A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 24080 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Francis Hospital, Inc | Tulsa, OK | Hospital |
| Oklahoma Surgical Hospital, Llc | Tulsa, OK | Hospital |
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Tulsa Spine & Specialty Hospital | Tulsa, OK | Hospital |
| Hillcrest Hospital South | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integris Ambulatory Care Corporation | 2365408465 | 382 |
| Neurological Surgery Inc | 2860472818 | 8 |
News Archive
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular testing professionals and leading education initiatives, discussions, and policy actions central to improving the development and application of molecular diagnostics, today reaffirmed its position that the vast majority of laboratory developed tests (LDTs), or laboratory developed procedures (LDPs)—a term coined by AMP to more appropriately capture the nature of these processes as medical services—should continue operating under the regulation of the Clinical Laboratory Improvement Amendments program at the Centers for Medicare & Medicaid Services, and not be subject to pre-market review by the U.S. Food and Drug Administration, as suggested in the draft guidance notification issued to Congress on July 31, 2014.
A delegation of five U.S. members of Congress traveling in Africa "pledged to woo the U.S. business community to invest in Rwanda," New Times/allAfrica.com reports. Rep. Gregory Meeks (D-N.Y.), who is leading the delegation, "said that Rwanda has proven to be one of the most favourable places to do business and it would be a major destination for U.S. investors," the publication writes. "I think the U.S. can continue to send individuals here, businessmen especially, that would invest in Rwanda and also help the people of Rwanda. I think this is very important," Meeks said.
Washington State University researchers have discovered a genetic variation that predicts how well people perform certain mental tasks when they are sleep deprived.
› Verified 9 days ago
| Entity Name | Neurological Surgery Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063401180 PECOS PAC ID: 2860472818 Enrollment ID: O20040721001138 |
News Archive
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular testing professionals and leading education initiatives, discussions, and policy actions central to improving the development and application of molecular diagnostics, today reaffirmed its position that the vast majority of laboratory developed tests (LDTs), or laboratory developed procedures (LDPs)—a term coined by AMP to more appropriately capture the nature of these processes as medical services—should continue operating under the regulation of the Clinical Laboratory Improvement Amendments program at the Centers for Medicare & Medicaid Services, and not be subject to pre-market review by the U.S. Food and Drug Administration, as suggested in the draft guidance notification issued to Congress on July 31, 2014.
A delegation of five U.S. members of Congress traveling in Africa "pledged to woo the U.S. business community to invest in Rwanda," New Times/allAfrica.com reports. Rep. Gregory Meeks (D-N.Y.), who is leading the delegation, "said that Rwanda has proven to be one of the most favourable places to do business and it would be a major destination for U.S. investors," the publication writes. "I think the U.S. can continue to send individuals here, businessmen especially, that would invest in Rwanda and also help the people of Rwanda. I think this is very important," Meeks said.
Washington State University researchers have discovered a genetic variation that predicts how well people perform certain mental tasks when they are sleep deprived.
› Verified 9 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular testing professionals and leading education initiatives, discussions, and policy actions central to improving the development and application of molecular diagnostics, today reaffirmed its position that the vast majority of laboratory developed tests (LDTs), or laboratory developed procedures (LDPs)—a term coined by AMP to more appropriately capture the nature of these processes as medical services—should continue operating under the regulation of the Clinical Laboratory Improvement Amendments program at the Centers for Medicare & Medicaid Services, and not be subject to pre-market review by the U.S. Food and Drug Administration, as suggested in the draft guidance notification issued to Congress on July 31, 2014.
A delegation of five U.S. members of Congress traveling in Africa "pledged to woo the U.S. business community to invest in Rwanda," New Times/allAfrica.com reports. Rep. Gregory Meeks (D-N.Y.), who is leading the delegation, "said that Rwanda has proven to be one of the most favourable places to do business and it would be a major destination for U.S. investors," the publication writes. "I think the U.S. can continue to send individuals here, businessmen especially, that would invest in Rwanda and also help the people of Rwanda. I think this is very important," Meeks said.
Washington State University researchers have discovered a genetic variation that predicts how well people perform certain mental tasks when they are sleep deprived.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan C Rahhal, MD 6767 South Yale Avenue, Suite A, Tulsa, OK 74136-3303 Ph: (918) 492-7587 | Ryan C Rahhal, MD 6767 South Yale Avenue, Suite A, Tulsa, OK 74136-3303 Ph: (918) 492-7587 |
News Archive
New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular testing professionals and leading education initiatives, discussions, and policy actions central to improving the development and application of molecular diagnostics, today reaffirmed its position that the vast majority of laboratory developed tests (LDTs), or laboratory developed procedures (LDPs)—a term coined by AMP to more appropriately capture the nature of these processes as medical services—should continue operating under the regulation of the Clinical Laboratory Improvement Amendments program at the Centers for Medicare & Medicaid Services, and not be subject to pre-market review by the U.S. Food and Drug Administration, as suggested in the draft guidance notification issued to Congress on July 31, 2014.
A delegation of five U.S. members of Congress traveling in Africa "pledged to woo the U.S. business community to invest in Rwanda," New Times/allAfrica.com reports. Rep. Gregory Meeks (D-N.Y.), who is leading the delegation, "said that Rwanda has proven to be one of the most favourable places to do business and it would be a major destination for U.S. investors," the publication writes. "I think the U.S. can continue to send individuals here, businessmen especially, that would invest in Rwanda and also help the people of Rwanda. I think this is very important," Meeks said.
Washington State University researchers have discovered a genetic variation that predicts how well people perform certain mental tasks when they are sleep deprived.
› Verified 9 days ago
Dr. Tyler Sean Auschwitz, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2000 South Wheeling, Ste 200, St. Johns Neuroscience Institute, Tulsa, OK 74104 Phone: 918-748-7854 | |
Joel Nathan Abramovitz, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2000 S Wheeling Ave, Suite 200, Tulsa, OK 74104 Phone: 918-748-7584 Fax: 918-293-3116 | |
Allan Gregory Rosenfeld, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 2000 S Wheeling Ave, Ste 200, Tulsa, OK 74104 Phone: 918-748-7854 Fax: 918-293-3116 | |
Dr. Brian James Hood, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 918-744-2345 | |
Daniel James Boedeker, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6767 S Yale Ave, Suite A, Tulsa, OK 74136 Phone: 918-492-7587 | |
Ryan Alexander Zengou, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6475 S Yale Ave Ste 308, Tulsa, OK 74136 Phone: 918-499-4000 Fax: 918-499-4001 | |
Mohammad Yashar S Kalani, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2000 S Wheeling Ave Ste 200, Tulsa, OK 74104 Phone: 918-748-7854 Fax: 918-403-6335 |